Wednesday, April 12, 2017 8:30:08 AM
The first experience of cytokine adsorption in a patient with sepsis after cardiac surgery
1,2 Dmitriy Shukevich, 1 Georgy Plotnikov, 1 Mikhail Rubtsov, 1 Vera Matveeva, 1,2 Evgeny Grigoryev 1 Complex Cardiovascular Disease Scientific Research Institute, Kemerovo, The Russian Federation 2 Kemerovo State Medical University, Kemerovo, The Russian Federation
J Vestnik Intensivnoi Terapii. 2016 No 4; pages 59-61
This case study reports on a 68-year old female patient will multiple morbidities who presented for elective cardiac surgery.
Case presentation
The patients history included rheumatic heart disease, biological prosthesis mitral valve replacement in 2003, primary bioprosthesis dysfunction, Cardiac insufficiency NYHA Functional Class IV, pulmonary arterial hypertension, persistent atrial fibrillation. Known comorbidities were hypertension stage II grade 3; chronic atrophic gastritis; secondary chronic duodenitis; latent form of chronic pyelonephritis, Gilbert disease.
After her chronic heart failure was stabilized, on-pump cardiac surgery (HLM time 200 mins, cross clamp time 110 mins) including mitral valve replacement and tricuspid annuloplasty was performed
Postoperatively low cardiac output syndrome with a cardiac index of 2.0 l/min/m2 was confirmed along with severe pulmonary hypertension and cardiac cachexia
Low cardiac output syndrome required noradrenaline infusion (0.5 µg/kg/min) and cardiac index stabilized at 2.5 l/min/m2 at the end of the 1st postoperative day
On day 2, noradrenaline dose requirements remained the same, cardiac index values were borderline, and therefore levosimendan infusion was started leading to catecholamine dose reduction, and stabilization of cardiac index and pulmonary hypertension
However, on day 2 creatinine values rose, hyperbilirubinemia was noted and blood gas analysis and X-ray suggested severe Acute Respiratory Distress Syndrome (ARDS)
Initiation of mechanical ventilation, antibacterial therapy, nutritional support and hemodiafiltration
Due to the presence of sepsis with a suspected infection source, a procalcitonin level greater than 10 ng/ml, and multiple organ failure, it was decided to additionally install a CytoSorb adsorber into the CVVHDF circuit
Treatment
One treatment with CytoSorb for 24 hours
CytoSorb was used in conjunction with CRRT (PrismaFlex, Gambro, Sweden) performed in CVVHDF mode
Blood flow rate: 165 ml/min
Anticoagulation: heparin
CytoSorb adsorber position: post-hemofilter
Measurements
Hemodynamics and demand for norepinephrine
Inflammatory parameters (IL-6)
Renal function (creatinine, diuresis)
Hepatic excretory function (bilirubin)
SOFA score
Blood composition (leucocytes, platelets)
Results
Clear reduction in norepinephrine demand from 1.19 µg/kg/min before hemoadsorption to 0.27 µg/kg/min after cessation of CytoSorb therapy
IL-6 levels could be decreased from 67,890 pg/ml to 45,000 pg/ml directly after cytokine adsorption with another drop to 12,000 pg/ml 24 hours after adsorption
Improvement of renal function with a consistent increase in diuresis accompanied by normalization of creatinine levels
Clear reduction in bilirubin levels during and after the course of the treatment
SOFA score reduction from 10 to 6 the next day following CytoSorb cessation
Immune balance recovered (increase in leukocytes count) as did platelet count which also rose to the lower normal range, INR returned to normal values (data not shown)
No bleeding complications or hemodynamic adsorption-related adverse effects during CytoSorb therapy session were registered
Patient Follow-Up
Creatinine levels rose again after 24 hours, so that hemodiafiltration sessions had to be repeated
Gradual regression of sepsis and multiple organ failure over the following days
Total ICU stay of 21 days with transfer to normal ward after ICU discharge
CONCLUSIONS
Treatment of this multi-morbidity patient resulted in the rapid stabilization of hemodynamics and a clear improvement in organ function
According to the medical team this experience with CytoSorb raises optimism for systemic inflammation correction in the setting of sepsis with an additional positive effect being bilirubin adsorption
Further studies are required to assess the indications, contraindications and outcomes for this method
Recent CTSO News
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:54 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM